Concurrent treatment of chronic psoriasis and asthma with ustekinumab

Ajay Amarnani, Ken S. Rosenthal, Jorge M. Mercado, Robert T. Brodell

Research output: Contribution to journalArticle

Abstract

A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalJournal of Dermatological Treatment
Volume25
Issue number1
DOIs
StatePublished - Feb 1 2014
Externally publishedYes

Fingerprint

Psoriasis
Asthma
Interleukin-23
Subcutaneous Injections
Therapeutics
Interleukin-12
Autoimmune Diseases
Chronic Disease
Monoclonal Antibodies
Maintenance
Exercise
Cytokines
Inflammation
Ustekinumab
Infection

Keywords

  • Asthma
  • Chronic inflammation
  • IL-12p40
  • Psoriasis
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

Concurrent treatment of chronic psoriasis and asthma with ustekinumab. / Amarnani, Ajay; Rosenthal, Ken S.; Mercado, Jorge M.; Brodell, Robert T.

In: Journal of Dermatological Treatment, Vol. 25, No. 1, 01.02.2014, p. 63-66.

Research output: Contribution to journalArticle

Amarnani, Ajay ; Rosenthal, Ken S. ; Mercado, Jorge M. ; Brodell, Robert T. / Concurrent treatment of chronic psoriasis and asthma with ustekinumab. In: Journal of Dermatological Treatment. 2014 ; Vol. 25, No. 1. pp. 63-66.
@article{b66495a6c1f64f9085c5655e7ad51057,
title = "Concurrent treatment of chronic psoriasis and asthma with ustekinumab",
abstract = "A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.",
keywords = "Asthma, Chronic inflammation, IL-12p40, Psoriasis, Ustekinumab",
author = "Ajay Amarnani and Rosenthal, {Ken S.} and Mercado, {Jorge M.} and Brodell, {Robert T.}",
year = "2014",
month = "2",
day = "1",
doi = "10.3109/09546634.2013.782095",
language = "English (US)",
volume = "25",
pages = "63--66",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Concurrent treatment of chronic psoriasis and asthma with ustekinumab

AU - Amarnani, Ajay

AU - Rosenthal, Ken S.

AU - Mercado, Jorge M.

AU - Brodell, Robert T.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.

AB - A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.

KW - Asthma

KW - Chronic inflammation

KW - IL-12p40

KW - Psoriasis

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84890490488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890490488&partnerID=8YFLogxK

U2 - 10.3109/09546634.2013.782095

DO - 10.3109/09546634.2013.782095

M3 - Article

C2 - 23469809

AN - SCOPUS:84890490488

VL - 25

SP - 63

EP - 66

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 1

ER -